126 related articles for article (PubMed ID: 33884654)
1. Safety analysis of ex vivo-expanded canine natural killer cells in a xenogeneic mouse model of graft-versus-host disease.
Kim CJ; Park SC; Lee SH; Lim YJ; Yoon M; Park JG; Baek YB; Cho KO; Hong JW; Shin DJ; Kim SK
J Leukoc Biol; 2022 Feb; 111(2):439-450. PubMed ID: 33884654
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3
Lee SH; Shin DJ; Kim Y; Kim CJ; Lee JJ; Yoon MS; Uong TNT; Yu D; Jung JY; Cho D; Jung BG; Kim SK; Suh GH
Front Immunol; 2018; 9():841. PubMed ID: 29755462
[TBL] [Abstract][Full Text] [Related]
3. Role of Natural Killer Cells in Intravenous Immunoglobulin-Induced Graft-versus-Host Disease Inhibition in NOD/LtSz-scidIL2rg(-/-) (NSG) Mice.
Gregoire-Gauthier J; Fontaine F; Benchimol L; Nicoletti S; Selleri S; Dieng MM; Haddad E
Biol Blood Marrow Transplant; 2015 May; 21(5):821-8. PubMed ID: 25596424
[TBL] [Abstract][Full Text] [Related]
4. Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice.
Xun C; Brown SA; Jennings CD; Henslee-Downey PJ; Thompson JS
Transplantation; 1993 Aug; 56(2):409-17. PubMed ID: 8356598
[TBL] [Abstract][Full Text] [Related]
5. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
6. Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice.
Batatinha H; Diak DM; Niemiro GM; Baker FL; Smith KA; Zúñiga TM; Mylabathula PL; Seckeler MD; Lau B; LaVoy EC; Gustafson MP; Katsanis E; Simpson RJ
Front Immunol; 2023; 14():1067369. PubMed ID: 37077913
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
Razmara AM; Farley LE; Harris RM; Judge SJ; Lammers M; Iranpur KR; Johnson EG; Dunai C; Murphy WJ; Brown CT; Rebhun RB; Kent MS; Canter RJ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631708
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
[TBL] [Abstract][Full Text] [Related]
9. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
10. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
11. S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model.
Wang F; Zhao S; Gu Z; Zhao X; Yang N; Guan L; Liu T; Wang L; Fang S; Zhu C; Luo L; Li M; Wang L; Gao C
Hematol Oncol; 2020 Feb; 38(1):89-102. PubMed ID: 31465552
[TBL] [Abstract][Full Text] [Related]
12. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells.
Shin DJ; Park JY; Jang YY; Lee JJ; Lee YK; Shin MG; Jung JY; Carson WE; Cho D; Kim SK
Vet Immunol Immunopathol; 2013 Jun; 153(3-4):249-59. PubMed ID: 23548866
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
[TBL] [Abstract][Full Text] [Related]
16. [Establishment of an xenogeneic acute graft-versus-host disease model in NOD/SCID mice by engraftment of G-CSF mobilized human mononuclear cells].
Gao L; Wang JM; Xie LN; Zhou H; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):87-91. PubMed ID: 18681307
[TBL] [Abstract][Full Text] [Related]
17. Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease.
Trujillo-Ocampo A; Cho HW; Herrmann AC; Ruiz-Vazquez W; Thornton AB; He H; Li D; Qazilbash MA; Ma Q; Porcelli SA; Shpall EJ; Molldrem J; Im JS
Cytotherapy; 2018 Aug; 20(8):1089-1101. PubMed ID: 30076070
[TBL] [Abstract][Full Text] [Related]
18. Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.
Chaudhry K; Dowlati E; Long MD; Geiger A; Lang H; Gomez EC; Muniraj N; Sanchez CE; Singh PK; Liu S; Bollard CM; Cruz CRY
Cytotherapy; 2022 Aug; 24(8):802-817. PubMed ID: 35589475
[TBL] [Abstract][Full Text] [Related]
19. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.
Baker J; Verneris MR; Ito M; Shizuru JA; Negrin RS
Blood; 2001 May; 97(10):2923-31. PubMed ID: 11342413
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]